Ovarian Cancer Drugs Market Expanding At A CAGR Of 23.7% For The Forecast Period From 2016 To 2022 : Grand View Research Inc.
San Francisco, 20 September 2019: The Report Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors) , By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 – 2022 The global ovarian cancer drugs market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market. Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest in...